Viral load-guided immunosuppression after lung transplantation (VIGILung)-study protocol for a randomized controlled trial.

ABSTRACT:

Background

Immunosuppression including high-dose calcineurin inhibitors (CNI) is essential after lung transplantation. Dosing is usually guided by therapeutic drug monitoring adjusted to target trough levels of CNIs to keep the balance between over-dose causing severe toxicity and increased risk of infections or under-dose with a risk of graft injury. Adaptation of CNI-based immunosuppression by monitoring of torque teno virus (TTV), a latent nonpathogenic DNA virus, measured in the whole blood in addition to conventional therapeutic drug monitoring may reduce the toxicity of immunosuppression with similar efficacy.

Methods/design

An open-label, randomized, controlled, parallel-group, multicenter trial in lung transplant recipients will be conducted to investigate the safety

SUBMITTER: Gottlieb J 

PROVIDER: S-EPMC7798016 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature